Vrettou, Maria
Yan, Liying
Nilsson, Kent W.
Wallén-Mackenzie, Åsa
Nylander, Ingrid
Comasco, Erika
Funding for this research was provided by:
Uppsala University
Article History
Received: 26 February 2021
Accepted: 14 July 2021
First Online: 28 July 2021
Competing interests
: LY is key shareholder of EpigenDx; all genetic analyses were performed in a blind manner. The other authors have no conflict of interest to declare.